John Vavricka - Atea Pharmaceuticals Chief Officer
| AVIR Stock | USD 3.30 0.10 2.94% |
Insider
John Vavricka is Chief Officer of Atea Pharmaceuticals
| Age | 61 |
| Address | 225 Franklin Street, Boston, MA, United States, 02110 |
| Phone | 857 284 8891 |
| Web | https://ateapharma.com |
John Vavricka Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Vavricka against Atea Pharmaceuticals stock is an integral part of due diligence when investing in Atea Pharmaceuticals. John Vavricka insider activity provides valuable insight into whether Atea Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Atea Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Atea Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Vavricka over three months ago Acquisition by John Vavricka of 140000 shares of Atea Pharmaceuticals at 4.63 subject to Rule 16b-3 |
Atea Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1425) % which means that it has lost $0.1425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3346) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals' management efficiency ratios could be used to measure how well Atea Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/27/2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Atea Pharmaceuticals' Non Current Assets Total are relatively stable compared to the past year. As of 11/27/2024, Non Currrent Assets Other is likely to grow to about 1.5 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Dornan | Elevation Oncology | 46 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Valerie MD | Elevation Oncology | 46 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| MBA MD | Immix Biopharma | 49 | |
| JD MBA | Immix Biopharma | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| MBA IV | Enveric Biosciences | 68 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Brian Sullivan | Elevation Oncology | N/A | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.14 |
Atea Pharmaceuticals Leadership Team
Elected by the shareholders, the Atea Pharmaceuticals' board of directors comprises two types of representatives: Atea Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atea. The board's role is to monitor Atea Pharmaceuticals' management team and ensure that shareholders' interests are well served. Atea Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atea Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Exec Officer | ||
| XiaoJian Zhou, Executive Development | ||
| Jayanthi Wolf, Executive Affairs | ||
| Wayne CPA, Executive Officer | ||
| Ariyapadi Krishnaraj, Vice Marketing | ||
| JeanPierre Sommadossi, Chairman, Founder | ||
| John Vavricka, Chief Officer | ||
| Nancy Agrawal, Executive Development | ||
| Maria MD, Chief Officer | ||
| Jonae Barnes, Senior Communications | ||
| Andrea JD, Executive CFO | ||
| Keith Pietropaolo, Senior Sciences | ||
| Adel Moussa, Executive Chemistry |
Atea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atea Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | (202.25 M) | ||||
| Shares Outstanding | 84.46 M | ||||
| Shares Owned By Insiders | 9.67 % | ||||
| Shares Owned By Institutions | 71.00 % | ||||
| Number Of Shares Shorted | 2.59 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 1.90 X |
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
| 0.68 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.76 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.68 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Atea Stock
| 0.72 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.59 | GILD | Gilead Sciences | PairCorr |
| 0.53 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.44 | LPCN | Lipocine | PairCorr |
| 0.43 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.